Introduction
Circulating levels of YKL-40 is a potential biomarker of acute and chronic inflammation and tissue remodelling, 1 -7 including systemic low-grade inflammation 8 and YKL-40 may participate in the innate immune response. 2 YKL-40 is regarded as an acute phase protein, since its plasma concentration is increased in inflammatory diseases. 1 -5 YKL-40 is a phylogenetically highly conserved chitin-, heparin-, and collagen-binding protein with homologues in vertebrates and invertebrates, and is a member of 'mammalian chitinase-like proteins'. 3, 9 The full biological functions of YKL-40 are unknown. YKL-40 is a growth factor for fibroblasts 10 and has an anti-catabolic effect preserving extracellular matrix during tissue remodelling. 11 stimulates migration and adhesion of endothelial cells and vascular smooth muscle cells (VSMCs), suggesting a role in angiogenesis, 12 -14 and may play a role in regulating response of cancer cells to hypoxia. 15 Atherosclerotic plaque macrophages express YKL-40, particularly macrophages that have infiltrated deeper into the lesion, and the highest YKL-40 mRNA expression is found in macrophages in the early atherosclerotic lesion. 16 Studies have suggested that high serum YKL-40 levels could be a prognostic biomarker of short survival. This is demonstrated in 80-year-old people 8 and in patients with Streptococcus pneumoniae bacteraemia, 1 and local or metastatic cancer. 7 Serum YKL-40 levels are elevated in patients with acute myocardial infarction (MI) 17, 18 and stable coronary artery disease (CAD), 19 and associated with the number of diseased vessels assessed by coronary angiography. 19 In the present study, we tested the hypothesis that elevated serum YKL-40 is a risk factor for acute coronary syndrome and death in patients with stable CAD.
Methods Patients
The patients were included in the randomized, placebo-controlled, multi-centre CLARICOR trial of patients with stable CAD treated for 2 weeks with oral clarithromycin 500 mg once daily (Klacid Uno w , Abbott, UK) or a matching placebo. 20 The patients had a diag- 
Follow-up
The patients had a 2.6 years follow-up period (median 2.77 years, interquartile range 0.23 year). Information about fatal and non-fatal admissions came from the Danish National Hospital Register, a database of all somatic hospital admissions. Information about death came from the Danish Central Civil Register, which records the vital status of all inhabitants in Denmark. Registration is 100% in these registers. On the basis of these registers, the coordinating centre collected death certificates and copies of hospital records during the follow-up period and forwarded each potential event separately to the event committee. As the observed event rate was lower than estimated, the steering committee extended the follow-up period from 2 to 3 years without analysing the data. Final data were collected April 2003. 20 
Outcomes
In the present study, we examined time from randomization to re-admission for: (1) unstable AP, (2) MI, (3) cardiovascular death, and (4) any death. We used pre-specified outcome flowchart forms to search for possible outcomes. Two randomly chosen members of the event committee, which consisted of three cardiologists, evaluated copies of hospital records and death certificates. In case of disagreement between the two evaluations, both forms together with copies of the record of the event were given to the third member, who had to select the most likely option. In cases with inadequate information, we classified the cause of death as unknown. 
YKL-40 analysis
Serum concentrations of YKL-40 were determined in duplicates by a commercial ELISA (Quidel, San Diego, CA, USA) using streptavidincoated microplate wells, a biotinylated-Fab monoclonal capture antibody, and an alkaline phosphatase-labelled polyclonal detection antibody. The recovery is 102%, detection limit 20 mg/L, intra-assay coefficient of variation (CV) , 5.0%, and inter-assay CVs are ,5.4% (low control) and ,6.7% (high control) in the 127 ELISA kits used for the analysis of the 4298 samples.
Statistical analysis
Cox-analyses were used to analyse the effect of one or more covariates on the time to an event. Extended Cox analyses including a covariate, time, and the interaction between time and the covariate as variables was used to test the proportionality assumption of the Cox model. The latter test was supplemented by a visual assessment of the log-log plots of the groups of the covariate. The assumption of the Cox model of linearity between a continuous covariate and the logarithm of the hazard ratio (HR) was assessed from an inspection of the relationship between the log HR and the mean value of the groups defined by the deciles of the covariate's distribution.
The proportionality assumption of the Cox model was fulfilled for all four events. The assumption for the Cox model of linearity between serum YKL-40 and the logarithm of the HR was not fulfilled in any of the analyses. Since there was no relationship between serum YKL-40 and the log of the HR of any of the events at serum YKL-40 levels below 82 mg/L and a linear relationship between the log of YKL40 and log HR above this value, we transformed serum YKL-40 using the transformation: Y¼log[max(82, serum YKL-40/mg/L)]. Age fulfilled the linearity assumption in case of the events all-cause death and cardiac death. For MI the transformation Y¼max(63, age/year) was used.
If transformed serum YKL-40 had a significant effect on the time to an event, we repeated the analysis adjusting for the known risk factors (age, sex, previous MI, smoking status, hypertension, diabetes mellitus).
Serum YKL-40 and prognosis in patients with stable CAD If the effect was still significant, we included selected indicators of treatment in the analysis. These factors were selected as follows: A random sample comprising one-half of the patients was selected and an analysis of the corresponding data material including as covariates the risk factors and all indicators of medical treatment (beta-blocker, ACE-inhibitor, calcium blocker, statin, magnyl, long-lasting nitrates, digoxin, diureticas, anti-arrhythmicas) was done. In this analysis, all covariates except the treatment indicators were forced to stay in the analysis which comprised a backward elimination using the likelihood ratio test with P ¼ 0.10 for removal of variables. The analysis was repeated using the other half of the data material. The treatment indicators selected were those that were retained in both of these two analyses. In all analyses the intervention indicator was forced to be included in the model.
Since the distributions of serum YKL-40 as well as those of log (YKL-40) differed significantly from the Gaussian distribution as assessed by the Shapiro-Wilk W test, non-parametric tests (MannWhitney test) were used to compare serum YKL-40 levels between patient groups.
The level of significance used was 0.05 and all tests were two-sided. To account for the inflation of the experiment wise Type I error due to multiple testing, we used the Bonferroni correction giving a significance level of 0.05/22¼0.0023 since 22 tests were done. The analyses were done using the SPSS version 15.0.
Results
Serum YKL-40 in relation to demographic and clinical characteristics of the patients with stable coronary artery disease
The demographic data and the relationship between serum concentrations of YKL-40 and the demographic data of the 4298 patients with stable CAD are described in Table 1 . The median serum YKL-40 was 110 mg/L (range 20-3047 mg/L). Serum YKL-40 was higher in patients with age .60 years, diabetes, hypertension, and in patients treated with calcium-antagonist, ACE-inhibitors, long-lasting nitrates, diuretics, and digoxin compared with patient without ( Table 1) . In contrast, patients treated with statin and magnyl had lower serum YKL-40 compared with untreated patients (Table 1 Table 2 ). In the analysis where the predictive significance of medical treatments was assessed while all risk factors were forced to remain in the analysis (see section on Statistical analysis), treatment with diuretics, digoxin, and statin were retained in the analysis of time to death. In the analysis of time to cardiovascular death, only treatment with digoxin was retained, and in the analysis of time to MI only ACE-inhibitor was retained. Following multivariable adjustment for cardiovascular risk factors and the selected medical treatment indicators Y contributed significantly to prediction of all-cause mortality (HR ¼ 1.62, 95% CI ¼ 1.37-1.90, P , 0.001) and cardiovascular mortality (HR ¼ 1.52, 95% CI ¼ 1.20-1.92, P ¼ 0.001) ( Table 2) .
For illustrative purposes, we show the event-free survival for unstable AP, MI, cardiovascular death, and all-cause mortality during the 2.6 years of follow-up for six serum YKL-40 groups in Figure 1A -D.
Discussion
We observed that high serum YKL-40 is a significant predictor for cardiovascular death, all-cause mortality, and MI in patients with stable CAD. Correcting the analyses for risk factors and selected medical treatments had a moderate impact on the HRs for allcause mortality and cardiovascular death, but eliminated the relation to MI. High serum YKL-40 was not associated with unstable AP, however the number of these patients was small.
The strengths of the present study are the size of the patient population, no losses to follow-up of events, and the ethnic homogeneity of the patient population. A weakness is that only serum YKL-40 was determined and not other potential prognostic biomarkers of MI and death in patients with CAD, e.g. C-reactive protein and B-type natriuretic peptide (BNP). 21 -26 In patients with stable CAD, the highest serum NT-pro-BNP level had an HR of 2.4 for all-cause mortality, 22 and the highest serum CRP level had an HR for cardiac death of 1.75, and for all-cause mortality of 1.78 during a 4.8 years follow-up period. 23 In the WIZARD trial including 3319 patients with stable CAD treated with azithromycin or placebo using serum CRP as a biomarker, the HR for all-cause mortality was 2.18 in the 3.1 years follow-up period. 24 In the present study, with a shorter follow-up (2.6 years), the HRs using serum YKL-40 as a biomarker were 1.38 for MI, 1.88 for cardiovascular death, and 2.01 for all-cause mortality. Due to differences in study populations, a direct comparison of HRs between different biomarkers in published studies is not valid. Age, sex, hypertension, diabetes, smoking habits, and previous myocardial infarction. d Treatment indicators for diuretics, digoxin, and statins were included in the analysis of death. In the analysis of cardiovascular death only the indicator of digoxin treatment was included. In the analysis of myocardial infarction only that of ACE-inhibitor treatment was included.
Since risk factors such as BMI, renal status, as well as other potential biomarkers were not measured in the present study the significance of serum YKL-40 in the prediction of all-cause death combined with those risk factors examined in the study by Pencina et al. 27 cannot be meaningfully assessed. Future studies with all relevant risk factors included should evaluate whether serum YKL-40 provide substantially better prediction of all-cause mortality in patients with stable CAD than that obtained using all known and relevant risk factors alone. Our results suggest that serum YKL-40 could be a new biomarker of acute and chronic inflammation in patients with stable CAD. Circulating YKL-40 may reflect the total burden of coronary atherosclerosis or identify a high-risk atherosclerosis phenotype with ongoing inflammation and atherosclerotic plaque formation. The molecular processes governing the induction of YKL-40 and its precise biological functions are unknown. In contrast to CRP, mainly produced by hepatocytes in response to high IL-6, YKL-40 is produced by macrophages and neutrophils in tissues with inflammation 2, 3, 5, 16, 28 and by differentiated macrophages and activated neutrophils. 29, 30 Interestingly, macrophages in atherosclerotic plaques express YKL-40 mRNA, particularly macrophages located deep in the lesion, and the highest YKL-40 expression is found in macrophages in the early lesion of atherosclerosis. 16 YKL-40 is also synthesized by VSMCs and promotes their migration and attachment, 12 -14 suggesting a role in the process of atherosclerotic plaque formation, where VSMCs are induced to migrate through the intima in response to exogenous signals.
In vitro YKL-40 is synthesized by swine VSMCs isolated from the thoracic aorta during the time of transition from a proliferating monolayer culture to a non-proliferating differentiated multilayer culture, and YKL-40 secretion continued as VSMCs reorganize and differentiate. 12 -14 This nodule forming process mimics some of the characteristics of the in vivo changes that occur in VSMCs following injury, where media SMCs dedifferentiate, migrate, and . These groups were formed by first dividing the serum YKL-40 levels into 10 groups using the deciles of the serum YKL-40 distribution. Then the first five of these groups were combined into one to obtain in all the above six groups.
contribute to the process of vascular restenosis and neointima formation. Furthermore, YKL-40 modulates vascular endothelial cell morphology by promoting the formation of branching tubules, indicating a role in angiogenesis by stimulating the migration and reorganization of vascular endothelial cells. 13, 14 However, some of the circulating YKL-40 in our group of patients with CAD who died of cancer during follow-up, may have originated from cancer cells. 7 Since YKL-40 is not disease specific co-morbidity should always be considered, and it has recently been found that elevated plasma YKL-40 predicted increased risk of gastrointestinal cancer in the general population.
31
Serum YKL-40 is increased up to seven-fold in both patients with stable CAD and after an acute ST-elevation MI (STEMI) 17 -19 and associated with the number of angiographically demonstrated coronary artery stenosis. 19 This supports the hypothesis, that YKL-40 plays a role in both the acute inflammatory process eliciting or responding to protect against the plaque instability and in the recovery and remodelling process after an acute STEMI by promoting the growth of new cardiomyocytes and inducing angiogenesis. YKL-40 may protect cardiomyocytes from undergoing apoptosis under ischaemia, since YKL-40 expression is up-regulated in cancer cells following hypoxia. 32 It has to be demonstrated in future studies, whether serum YKL-40 will fulfil the three fundamental requirements to be a potentially useful new biomarker: (1) analytical methods that allow reliable measurement are available to every clinician; (2) provide prognostic information in multiple studies and diverse populations, with incremental prognostic information when added to validated risk scores; and (3) help the clinician to manage patients. 33 Only requirement (1) is fulfilled at present, since we used a commercially available YKL-40 ELISA. This method takes less than 4 h, has low intra-and inter-assay coefficients of variation, and the intraclass correlation coefficient indicated reasonable reliability of serum YKL-40 measurements and relatively small variation in healthy subjects. 34 In conclusion, serum YKL-40 was found to be a biomarker for MI, cardiovascular death, and all-cause mortality in patients with stable CAD. The mechanism(s) involved cannot be resolved from the present study and has to be clarified in future studies. We speculate if serum YKL-40 could be used for monitoring the sufficiency of medical treatment of patients with stable CAD and thereby assist in the reduction of the high occurrence of non-fatal and fatal cardiovascular events in these patients.
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